BR112017009289A2 - métodos de administrar composições de amantadina - Google Patents
métodos de administrar composições de amantadinaInfo
- Publication number
- BR112017009289A2 BR112017009289A2 BR112017009289A BR112017009289A BR112017009289A2 BR 112017009289 A2 BR112017009289 A2 BR 112017009289A2 BR 112017009289 A BR112017009289 A BR 112017009289A BR 112017009289 A BR112017009289 A BR 112017009289A BR 112017009289 A2 BR112017009289 A2 BR 112017009289A2
- Authority
- BR
- Brazil
- Prior art keywords
- methods
- administering amantadine
- compositions
- amantadine compositions
- administering
- Prior art date
Links
- DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 title abstract 2
- 229960003805 amantadine Drugs 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 208000016285 Movement disease Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
- A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
métodos de administração de amantadina para melhorar distúrbios de movimento são descritos, assim como composições adequadas para tal.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462075137P | 2014-11-04 | 2014-11-04 | |
PCT/US2015/058872 WO2016073510A1 (en) | 2014-11-04 | 2015-11-03 | Methods of administering amantadine compositions |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112017009289A2 true BR112017009289A2 (pt) | 2017-12-19 |
Family
ID=55909712
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112017009289A BR112017009289A2 (pt) | 2014-11-04 | 2015-11-03 | métodos de administrar composições de amantadina |
Country Status (14)
Country | Link |
---|---|
US (1) | US20160228388A1 (pt) |
EP (2) | EP3215132B1 (pt) |
JP (1) | JP6735020B2 (pt) |
CN (1) | CN107205950B (pt) |
AU (1) | AU2015343199B2 (pt) |
BR (1) | BR112017009289A2 (pt) |
CA (1) | CA2966195C (pt) |
ES (1) | ES2865278T3 (pt) |
HU (1) | HUE055779T2 (pt) |
MX (1) | MX2017005578A (pt) |
PL (1) | PL3215132T3 (pt) |
PT (1) | PT3215132T (pt) |
SI (1) | SI3215132T1 (pt) |
WO (1) | WO2016073510A1 (pt) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014204933A1 (en) | 2013-06-17 | 2014-12-24 | Adamas Pharmaceuticals, Inc. | Amantadine compositions and methods of use |
CA3072764A1 (en) | 2017-08-24 | 2019-02-28 | Adamas Pharma, Llc | Amantadine compositions, preparations thereof, and methods of use |
TR201720406A2 (tr) | 2017-12-14 | 2019-07-22 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Bi̇r i̇skelet kasi gevşeti̇ci̇si̇ ve bi̇r multi̇pl skleroz tedavi̇ edi̇ci̇ ajan i̇çeren kombi̇nasyonlar |
WO2019245513A2 (en) | 2018-06-21 | 2019-12-26 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | A combination comprising fingolimod and amantadine |
TR201818307A2 (tr) * | 2018-11-30 | 2020-06-22 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Di̇meti̇l fumarat i̇çeren bi̇r kompozi̇syon |
TR201818859A2 (tr) | 2018-12-07 | 2020-06-22 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Di̇meti̇l fumarat ve en az bi̇r kas gevşeti̇ci̇ ajan i̇çeren bi̇r kombi̇nasyon |
TR201819202A2 (tr) | 2018-12-12 | 2020-06-22 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Bi̇r multi̇pl skleroz ajani ve en az bi̇r kas relaksan ajan i̇çeren bi̇r kombi̇nasyon |
TR201820976A2 (tr) * | 2018-12-28 | 2020-07-21 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Fi̇ngoli̇mod ve bi̇r spazmoli̇ti̇k i̇çeren farmasöti̇k kombi̇nasyonlar |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5221536A (en) | 1990-05-07 | 1993-06-22 | Alza Corporation | Dosage form indicated for the management of abnormal posture, tremor and involuntary movement |
US5358721A (en) | 1992-12-04 | 1994-10-25 | Alza Corporation | Antiviral therapy |
AUPN605795A0 (en) | 1995-10-19 | 1995-11-09 | F.H. Faulding & Co. Limited | Analgesic pharmaceutical composition |
WO2006053067A2 (en) * | 2004-11-09 | 2006-05-18 | Prestwick Pharmaceuticals, Inc. | Combination of amantadine and a tetrabenazine compound for treating hyperkinetic disorders |
US7619007B2 (en) | 2004-11-23 | 2009-11-17 | Adamas Pharmaceuticals, Inc. | Method and composition for administering an NMDA receptor antagonist to a subject |
WO2006058236A2 (en) | 2004-11-24 | 2006-06-01 | Neuromolecular Pharmaceuticals, Inc. | Composition comprising an nmda receptor antagonist and levodopa and use thereof for treating neurological disease |
US8574626B2 (en) | 2004-12-03 | 2013-11-05 | Osmotica Kereskedelmi és Szolgáltató KFT | Osmotic device containing amantadine and an osmotic salt |
WO2006089066A1 (en) * | 2005-02-15 | 2006-08-24 | Neuromolecular Pharmaceuticals, Inc. | Combinations therapy for treatment of demyelinating conditions |
AU2006244297A1 (en) | 2005-04-06 | 2006-11-16 | Adamas Pharmaceuticals, Inc. | Methods and compositions for treatment of CNS disorders |
US7981930B2 (en) | 2007-03-13 | 2011-07-19 | Adamas Pharmaceuticals, Inc. | Compositions and kits for treating influenza |
CN106389381A (zh) | 2009-12-02 | 2017-02-15 | 阿达玛斯医药公司 | 金刚烷胺组合物及其使用方法 |
WO2014093475A1 (en) * | 2012-12-11 | 2014-06-19 | Acorda Therapeutics, Inc. | Methods for treating parkinson's disease using aminopyridines |
WO2014204933A1 (en) * | 2013-06-17 | 2014-12-24 | Adamas Pharmaceuticals, Inc. | Amantadine compositions and methods of use |
-
2015
- 2015-11-03 WO PCT/US2015/058872 patent/WO2016073510A1/en active Application Filing
- 2015-11-03 JP JP2017522637A patent/JP6735020B2/ja active Active
- 2015-11-03 PT PT158575910T patent/PT3215132T/pt unknown
- 2015-11-03 AU AU2015343199A patent/AU2015343199B2/en active Active
- 2015-11-03 MX MX2017005578A patent/MX2017005578A/es active IP Right Grant
- 2015-11-03 PL PL15857591T patent/PL3215132T3/pl unknown
- 2015-11-03 BR BR112017009289A patent/BR112017009289A2/pt not_active Application Discontinuation
- 2015-11-03 US US14/931,546 patent/US20160228388A1/en not_active Abandoned
- 2015-11-03 CA CA2966195A patent/CA2966195C/en active Active
- 2015-11-03 EP EP15857591.0A patent/EP3215132B1/en active Active
- 2015-11-03 SI SI201531585T patent/SI3215132T1/sl unknown
- 2015-11-03 HU HUE15857591A patent/HUE055779T2/hu unknown
- 2015-11-03 EP EP21153566.1A patent/EP3909569A1/en not_active Withdrawn
- 2015-11-03 CN CN201580072014.7A patent/CN107205950B/zh active Active
- 2015-11-03 ES ES15857591T patent/ES2865278T3/es active Active
Also Published As
Publication number | Publication date |
---|---|
EP3215132A1 (en) | 2017-09-13 |
CA2966195A1 (en) | 2016-05-12 |
EP3215132A4 (en) | 2018-07-11 |
JP2017533211A (ja) | 2017-11-09 |
CN107205950B (zh) | 2021-06-04 |
US20160228388A1 (en) | 2016-08-11 |
ES2865278T3 (es) | 2021-10-15 |
AU2015343199A1 (en) | 2017-05-18 |
CN107205950A (zh) | 2017-09-26 |
MX2017005578A (es) | 2018-01-11 |
CA2966195C (en) | 2024-04-30 |
SI3215132T1 (sl) | 2021-11-30 |
PL3215132T3 (pl) | 2021-10-11 |
PT3215132T (pt) | 2021-05-07 |
EP3215132B1 (en) | 2021-01-27 |
AU2015343199B2 (en) | 2021-04-08 |
HUE055779T2 (hu) | 2021-12-28 |
WO2016073510A1 (en) | 2016-05-12 |
JP6735020B2 (ja) | 2020-08-05 |
EP3909569A1 (en) | 2021-11-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12018500718A1 (en) | Compounds useful as modulators of trpm8 | |
MX2023008686A (es) | Polinucleotidos moduladores. | |
PH12017500408B1 (en) | Heteroaryl compounds as btk inhibitors and uses thereof | |
CO2017001884A2 (es) | Polimorfos de selinexor | |
BR112017009289A2 (pt) | métodos de administrar composições de amantadina | |
PH12017502255A1 (en) | Nrf2 regulators | |
CR20150370A (es) | Compuestos antivirales | |
PH12016501151A1 (en) | Nrf2 regulators | |
EA201691988A1 (ru) | Производные бороновой кислоты и их терапевтическое применение | |
EA201691594A1 (ru) | Циклопропиламины в качестве ингибиторов lsd1 | |
EA201591728A1 (ru) | Гетероциклические соединения и способы их применения | |
EA202091397A1 (ru) | Бензохинолоновые ингибиторы vmat2 | |
MX2018000451A (es) | Composiciones de plinabulina. | |
EA201790505A1 (ru) | Соединение, нацеленое на ил-23а и фно-альфа, и его применение | |
EA201790570A1 (ru) | Модуляторы р2х7 | |
BR112017006552A2 (pt) | composições e métodos para inibir a atividade biológica de biomoléculas solúveis | |
BR112017028549A2 (pt) | derivados de pirimidina como inibidores de btk e usos dos mesmos | |
PH12017500459A1 (en) | Azetidinyloxyphenylpyrrolidine compounds | |
EA201890898A1 (ru) | Новые соединения и конъюгаты криптофицина, их получение и их терапевтическое применение | |
DOP2016000073A (es) | Composiciones y métodos para inhibir la expresión del gen alas1 | |
CO2017005566A2 (es) | Péptidos cíclicos derivados de cd44v6 para el tratamiento de enfermedades relacionadas con cánceres y angiogénesis | |
CR20160448A (es) | Nuevos derivados de piridina | |
CR20170090A (es) | Derivados de terahidroquinolina como inhibidores del bromodominio | |
IN2014CH00151A (pt) | ||
MX2015016603A (es) | Composiciones de corticosteroides. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B09B | Patent application refused [chapter 9.2 patent gazette] |